Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1419&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1420&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1418&sort=award_amount" }, "data": [ { "type": "Grant", "id": "4470", "attributes": { "award_id": "1458952", "title": "RII Track-1: Gravitational Wave Astronomy and the Appalachian Freshwater Initiative", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Office Of The Director", "EPSCoR Research Infrastructure" ], "program_reference_codes": [], "program_officials": [ { "id": 15299, "first_name": "Chinonye", "last_name": "Nnakwe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-08-01", "end_date": "2023-07-31", "award_amount": 20000000, "principal_investigator": { "id": 15304, "first_name": "Juliana", "last_name": "Serafin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1289, "ror": "", "name": "Higher Education Policy Commission", "address": "", "city": "", "state": "WV", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 15300, "first_name": "Fred L", "last_name": "King", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15301, "first_name": "John", "last_name": "Maher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15302, "first_name": "Ami M", "last_name": "Smith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15303, "first_name": "Sarah", "last_name": "Tucker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1289, "ror": "", "name": "Higher Education Policy Commission", "address": "", "city": "", "state": "WV", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract\n\nProposal Number:\t\tIIA-1458952\n\nProposal Title:\tRII Track-1: Gravitational Wave Astronomy and the Appalachian Freshwater Initiative\n\nInstitution:\t\t\tHigher Education Policy Commission\n\nNon-technical Description\nResearch Consortia will be established in the strategic and WV-specific areas of freshwater quality research and detection of gravitational waves (GWs). Research on water quality is motivated by the state?s prioritization of management of water resources. An interdisciplinary team of researchers with expertise in biology, ecology, environmental engineering, chemistry, and geology will develop analytical facilities and expertise through the Appalachian Freshwater Initiative (AFI) to understand and detect ecological and biological impacts of complex mixtures of contaminants in water under varying climate change scenarios. Research on GW detection will take advantage of the Robert C. Byrd Green Bank Telescope in Green Bank, WV. This team, consisting of astrophysicists and engineers, will build the physical and human infrastructure necessary for researchers to directly detect and characterize gravitational waves. The project will broaden participation of minorities and females in Science, Technology, Engineering and Mathematics (STEM) professions through continuing education workshops and scholarships. Public engagement will occur through citizen science efforts, as well as museum and planetarium displays and programs.\n\nTechnical Description \nThe freshwater quality research focuses on detecting novel and dilute contaminants and pathogens, understanding the complex chemical interactions and pathogen characteristics, predicting contaminant transport, toxicity, and degradation pathways, and understanding how climate-related changes in precipitation regimes affect biological communities. The group will develop rapid, sensitive, low-cost sensors for contaminants and pathogens that have the potential to impact aquatic ecosystems and the freshwater supply. Researchers will work to understand the sub-lethal, chronic, and cumulative effects of the chemical, biological, and physical contaminants in Appalachian streams and rivers. In addition, the group will model effects of multi-contaminant mixtures on ecological communities. Detection of GWs and the characterization of GW sources will allow studies ranging from early universe cosmology to formation and evolution of galaxies to populations of compact objects in the local universe to tests of general relativity and alternative theories of gravity. The sensitivity of pulsar timing arrays to nanoHertz frequency gravitational waves emitted by supermassive black-hole binaries will be enhanced through addition of more millisecond pulsars to the array, development of improved algorithms for characterization of pulsars, better understanding of the source populations, and improvements in the sensitivity and efficiency of algorithms for detecting GW signatures.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6554", "attributes": { "award_id": "3OT2HL158287-01S5", "title": "NHLBI Maternal Morbidity and Mortality (3M) Administrative Coordinating Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21952, "first_name": "Catherine", "last_name": "Stoney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-25", "end_date": "2022-09-25", "award_amount": 20000000, "principal_investigator": { "id": 21953, "first_name": "Paula Darby DARBY", "last_name": "Lipman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 849, "ror": "", "name": "WESTAT, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10798", "attributes": { "award_id": "2229873", "title": "AI Institute for Transforming Education for Children with Speech and Language Processing Challenges", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Directorate for STEM Education (EDU)", "AI Research Institutes" ], "program_reference_codes": [], "program_officials": [ { "id": 2579, "first_name": "Fengfeng", "last_name": "Ke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-01-15", "end_date": "2027-12-31", "award_amount": 20000000, "principal_investigator": { "id": 26875, "first_name": "Venugopal", "last_name": "Govindaraju", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 4900, "first_name": "Julie A", "last_name": "Kientz", "orcid": "https://orcid.org/0000-0001-7437-7861", "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": "['https://medium.com/families-and-tech', 'https://twitter.com/FamilyandTechUW']", "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 26872, "first_name": "Pamela A", "last_name": "Hadley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26873, "first_name": "David", "last_name": "Feil-Seifer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26874, "first_name": "Jinjun", "last_name": "Xiong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 422, "ror": "", "name": "SUNY at Buffalo", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "It is estimated that more than 3.4 million children need speech and language related services in the US school system, yet there are less than sixty-one thousand speech-language pathologists (SLPs) to serve them. The COVID-19 pandemic has further exacerbated this gap, making it almost impossible for SLPs to provide individualized services for children. The AI Institute for Transforming Education for Children with Speech and Language Processing Challenges aims to close this gap by developing advanced AI technologies to scale SLPs' availability and services such that no child in need of speech and language services is left behind. Towards this end, the Institute proposes to develop two novel AI solutions: (1) the AI Screener to enable universal early screening for all children, and (2) the AI Orchestrator to work with SLPs to provide individualized interventions for children with their formal Individualized Educational Plan (IEP). In developing these solutions, the Institute will advance foundational AI technologies, enhance understanding of children's speech and language development, serve as a nexus point for special education stakeholders, and represent a fundamental paradigm shift in how SLPs serve children in need of ability based speech and language services.\n\nThe AI Screener will be initially deployed in early childhood classrooms and will analyze video and audio streams of children's classroom interactions, derive conventional speech and language measures used by SLPs, and assess novel and hard to obtain automaticity measures. The AI Orchestrator is a superset of the AI Screener with its main application in the public school classrooms. It will help SLPs to administer a wide range of evidence-based interventions and assess their effects on meeting children's individual IEP learning targets. At the core of the Orchestrator is a robust multi-agent reinforcement learning framework that can evaluate the potential benefits of different intervention practices and recommend those most appropriate for each child. Both solutions will push significant advances in self-supervised learning to address sparse and noisy data issues, multimodality perception, learning material rewriting and enrichment, and edge AI for real time processing. The Institute will develop human centered AI design methodologies to embody the solutions in a form appropriate for children’s learning. Education research and the learning sciences will inform the initial prototyping and validation, and will derive valuable insights from the field deployed solutions.\n\nThe National Center for Special Education Research at the Institute of Education Sciences of the US Department of Education is partnering with NSF to provide funding for the Institute.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7790", "attributes": { "award_id": "1U24MD016258-01", "title": "RADx-UP CDCC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 7440, "first_name": "DOROTHY M", "last_name": "CASTILLE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-27", "end_date": "2022-06-30", "award_amount": 20162334, "principal_investigator": { "id": 23601, "first_name": "Michael", "last_name": "Cohen-Wolkowiez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23602, "first_name": "Giselle", "last_name": "Corbie-Smith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23603, "first_name": "WARREN A.", "last_name": "KIBBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "There is an urgent need to reduce disparities in COVID-19 associated morbidity and mortality outcomes in historically marginalized and vulnerable populations disproportionately affected by the COVID-19 pandemic. To address this need the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) program will support Community-Engaged Testing Research Projects and Social, Ethical and Behavioral Implications (SEBI) Research Projects to understand SARS-CoV-2 infection patterns and increase access and effectiveness of diagnostic methods in underserved and/or vulnerable populations. The Duke Clinical Research Institute (DCRI), the UNC Center for Health Equity Research (CHER), and Community-Campus Partnerships for Health (CCPH) propose to serve as the Coordination and Data Collection Center (CDCC) to provide management, direction, and overall coordination of the RADx-UP consortium. Together, our multidisciplinary experience in project coordination; COVID-19 thought leadership; regulatory science; community engagement; health equity research; social justice; adult and child research; statistics; data science; and clinical research informatics will advance the objectives of the projects in the RADx-UP Program. Our overarching goal is to implement a community-centered approach and establish an effective, flexible, participatory, and sustainable CDCC that will serve as the infrastructure to maximize the community impact of projects in the RADx-UP Program. To achieve this vision, we will establish a program framework comprised of four cores. Our Administration and Coordination Core, in collaboration with NIH scientific staff, will facilitate the work of the RADx-UP Program in overarching administrative management. The COVID-19 Testing Core will advise and guide COVID-19 testing protocols; curate emergent testing data; and administer the Rapid Pilot Studies Program. The Community and Health System Engagement Core will support a community of practice across the RADx-UP Program; provide support in exchanging best practices across communities on recruitment, engagement, and retention of study participants; and coordinate the dissemination of study findings from RADx-UP projects. The Data Science and Biostatistics Core will manage data collection, integration, and sharing for the RADx-UP Program including merging and harmonization of multiple and diverse data sources and provide data standards, data collection design, and biostatistics consulting services. The RADx-UP CDCC goals will be met using established infrastructure and subject matter experts and will be customized to meet the variable needs of the RADx-UP community. Using the highest research standards, our team will accomplish the goals set out by the NIH in managing this critically important collaborative effort.", "keywords": [ "2019-nCoV", "Acceleration", "Address", "Adult", "Affect", "Back", "Behavioral", "Biometry", "Biostatistics Core", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Child", "Clinical Research", "Collaborations", "Communities", "Community Health Systems", "Community of Practice", "Consult", "Custom", "Data", "Data Collection", "Data Science", "Data Sources", "Diagnostic", "Diagnostic Procedure", "Effectiveness", "Ensure", "Ethics", "Funding", "Future", "Goals", "Health", "Inequality", "Infection", "Informatics", "Infrastructure", "Leadership", "Morbidity - disease rate", "Office of Administrative Management", "Outcome", "Participant", "Pattern", "Pilot Projects", "Plant Roots", "Population Programs", "Protocols documentation", "Public Health", "Research", "Research Institute", "Research Personnel", "Research Project Grants", "Research Support", "Science", "Scientific Advances and Accomplishments", "Services", "Social Justice", "Structure", "Testing", "Underserved Population", "United States National Institutes of Health", "Universities", "Virus", "Vision", "Vulnerable Populations", "Work", "community center", "data management", "data standards", "data warehouse", "design", "disparity reduction", "diverse data", "experience", "flexibility", "health disparity", "health equity", "improved", "infrastructure development", "interest", "lens", "mortality", "multidisciplinary", "pandemic disease", "prevent", "programs", "recruit", "social", "statistics" ], "approved": true } }, { "type": "Grant", "id": "11049", "attributes": { "award_id": "3U24TR001608-07S1", "title": "ACTIV-6", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23494, "first_name": "Sarah", "last_name": "Dunsmore", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-26", "end_date": "2023-06-30", "award_amount": 20600000, "principal_investigator": { "id": 21094, "first_name": "DANIEL K.", "last_name": "BENJAMIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23026, "first_name": "Susanna", "last_name": "Naggie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24010, "first_name": "Adrian", "last_name": "Hernandez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that first emerged in December 2019 and has since caused a global pandemic unseen in almost a century with respect to the number of cases and overall mortality. Over 2020, advances were made for treatment of COVID-19 and several vaccinations have received emergency use authorization for prevention of SARS-CoV-2 infections. However, the pandemic continues to evolve with new variants and surges of infections in different regions of the world, requiring an ongoing evidence-generating platform, in particular for the oral treatment of COVID-19 infection in the outpatient setting. To address this unmet need the Duke Clinical Research Institute, Vanderbilt University Medical Center and partners are coming together to coordinate ACTIV-6 as a platform with a master clinical trial protocol that can serve as an evidence generating system for prioritized drugs repurposed from other indications with an established safety record and preliminary evidence of clinical efficacy for the treatment of COVID-19.", "keywords": [ "Address", "Adult", "Agreement", "Budgets", "Child", "Childhood", "Clinical", "Clinical Research", "Clinical Trials", "Collection", "Complement", "Complex", "Conduct Clinical Trials", "Consumption", "Contracts", "Country", "Enrollment", "Ensure", "Feasibility Studies", "Funding", "Funding Opportunities", "Goals", "Health", "Infant", "Informatics", "Information Dissemination", "Information Systems", "Infrastructure", "Institution", "Institutional Review Boards", "International", "Language", "Learning", "Measures", "Methods", "Monitor", "Multi-Institutional Clinical Trial", "Multicenter Trials", "National Institute of Child Health and Human Development", "Participant", "Patients", "Pediatrics", "Principal Investigator", "Process", "Protocols documentation", "Public Health", "Records", "Registries", "Research", "Research Design", "Research Institute", "Research Methodology", "Research Personnel", "Research Support", "Resources", "Site", "Standardization", "Time", "Underserved Population", "United States", "United States National Institutes of Health", "Universities", "Vision", "Work", "biomedical informatics", "collaborative trial", "cost", "design", "electronic consent", "human subject", "improved", "innovation", "interoperability", "multi-site trial", "novel", "novel therapeutics", "operation", "programs", "recruit", "response", "stem", "success", "trial design", "web portal" ], "approved": true } }, { "type": "Grant", "id": "9380", "attributes": { "award_id": "3UM1AI068619-15S2", "title": "CoVPN 3008, Multi-Center, Randomized, Efficay Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23090, "first_name": "Judith A.", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-12-01", "end_date": "2023-11-30", "award_amount": 21074900, "principal_investigator": { "id": 23599, "first_name": "MYRON S.", "last_name": "COHEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1623, "ror": "", "name": "FAMILY HEALTH INTERNATIONAL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23600, "first_name": "WAFAA M.", "last_name": "EL-SADR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 1623, "ror": "", "name": "FAMILY HEALTH INTERNATIONAL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching goal of the HIV Prevention Trials Network (HPTN) is to identify acceptable, feasible, safe, effective and scalable interventions for HIV prevention that address the needs of populations at risk in the U.S. and around the world. The HPTN will address this goal by identifying: 1) new biomedical products and tools for HIV prevention that have unique characteristics, such as longer duration of action, new targets for inhibition of HIV replication, or as multipurpose prevention technologies (MPTs); and (2) integrated strategies that optimize use of proven efficacious prevention interventions and new tools tailored to specific populations at risk to achieve maximal public health impact. These interventions will be evaluated in priority populations for HIV prevention including women in sub-Saharan Africa, young men and women at risk, men who have sex with men (MSM), transgender women (TGW) who have sex with men, female sex workers (FSW) and persons who inject drugs (PWID). The specific aims of this research will be 1) To design and conduct studies of long-acting antiretroviral (ARV) agents and delivery systems for pre-exposure prophylaxis (PrEP); 2) To design and conduct studies to evaluate MPTs that concurrently prevent HIV and pregnancy, sexually transmitted infections (STIs) or opioid dependence; 3) To design and conduct studies in collaboration with the HIV Vaccine Trials Network to evaluate broadly neutralizing antibodies (bnAbs), alone and in combination, for PrEP; 4) To design and conduct integrated strategies for HIV prevention. For the first three aims, the HPTN will use a sequential multi-phase drug development strategy for the evaluation of new candidates for prevention. Phase 1 and 2 studies will be conducted for the evaluation of appropriate dose, safety and tolerability of the agent(s). The most promising systemic agents will be advanced using the criteria for a favorable target product profile for new agents including highly effective and durable protection against HIV, minimal adverse effects and drug interactions, high levels of user acceptability, and a high barrier to viral resistance. Efficacious biomedical prevention interventions will be incorporated into integrated strategy study designs that also include socio- behavioral interventions tailored to the HIV prevention imperatives and contextual needs of the specific populations at risk for HIV infection. Socio-Behavioral research (SBR) will be integral to the success of all aspects of the proposed HPTN HIV prevention agenda. Supportive SBR will be used to strengthen biomedical HIV product development (i.e. to inform user preference and ultimately product design for Phase 1-3 clinical trials), while integrative SBR will play a key role in the process of designing and adapting behavioral and structural interventions to complement biomedical interventions in integrated strategy studies. The HPTN will design and conduct the research through collaboration with its scientific leadership, its research teams, community partners, research participants, pharmaceutical companies and funders.", "keywords": [ "AIDS prevention", "Address", "Adverse effects", "Affect", "Africa South of the Sahara", "Anti-Retroviral Agents", "Behavioral", "COVID-19", "COVID-19 Prevention Network", "Characteristics", "Clinical Trials", "Collaborations", "Communities", "Complement", "Discrimination", "Drug Interactions", "Epidemic", "Evaluation", "Face", "Goals", "HIV", "HIV Infections", "HIV Vaccine Trials Network", "HIV prevention trials network", "Individual", "Injecting drug user", "Intervention", "Leadership", "New Agents", "Opiate Addiction", "Participant", "Pharmacologic Substance", "Phase", "Play", "Population", "Populations at Risk", "Poverty", "Pregnancy", "Prevention", "Process", "Public Health", "RNA vaccine", "Randomized", "Research", "Research Design", "Research Personnel", "Risk", "SARS-CoV-2 variant", "Safety", "Sexually Transmitted Diseases", "Site", "Social Behavior", "Structure", "System", "Technology", "Woman", "appropriate dose", "design", "drug development", "female sex worker", "member", "men who have sex with men", "neutralizing antibody", "phase 1 designs", "pre-exposure prophylaxis", "preference", "prevent", "preventive intervention", "product development", "social stigma", "success", "tool", "transgender women who have sex with men", "variants of concern", "viral resistance", "young man", "young woman" ], "approved": true } }, { "type": "Grant", "id": "8204", "attributes": { "award_id": "75N92021C00013-0-9999-1", "title": "THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE DELIVERABLE DUE DATES FOR RADX TECH PROJECT 2200", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-16", "end_date": "2022-04-15", "award_amount": 21300000, "principal_investigator": { "id": 24039, "first_name": "WALLY", "last_name": "NARAJOWSKI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Our DASH-HT molecular diagnostic system will detect SARS-CoV-2 RNA in asymptomatic subjects in 12 minutes with a throughput of 30 per hour. Specimens can be nasal or nasopharyngeal swabs. Less than 1 minute of operator time is required to elute specimens in the cartridge and scan barcodes. The cartridge, which is closed after removing the swab, contains all reagents needed for extraction, purification and RT-qPCR. 40 cycles of qPCR are performed in less than 5 minutes after sample prep which takes 7 minutes. Six processing units are housed in a cabinet that contains power and environmental control system so the system can be run outdoors year round. It is small and light enough to be transported as checked luggage on domestic airlines. Cartridges are designed to be stable for at least 1 year at ambient temperatures of 4 to 30 degrees C. They are creditcard sized for high density packaging. Our SARS-CoV-2 RT-qPCR assay has analytical sensitivity of 10 copies, and has been multiplexed with a process control. Alpha prototypes are currently running in CIGHT R&D labs. They are recently-modified versions of a point of care system that has been in development for 3 years. It was scheduled to go into clinical trails with flu A/B and STI panels at the end of this year. While this high-throughput version will immediately fill a critical gap in COVID testing, systems can be scaled down to meet needs of urgent care clinics and doctors offices that may be involved in the future.", "keywords": [ "2019-nCoV", "Bar Codes", "Biological Assay", "COVID testing", "COVID-19 detection", "Clinic", "Clinical", "Development", "Future", "Hour", "Light", "Modification", "Point-of-Care Systems", "Process", "RADx Tech", "RNA", "Reagent", "Running", "Sampling", "Scanning", "Schedule", "Specimen", "Swab", "System", "Temperature", "Time", "Update", "density", "design", "diagnostic platform", "flu", "molecular diagnostics", "nasal swab", "nasopharyngeal swab", "prototype", "research and development", "urgent care" ], "approved": true } }, { "type": "Grant", "id": "9363", "attributes": { "award_id": "1S10AI162059-01", "title": "Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6245, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-11-05", "end_date": "2022-10-31", "award_amount": 21360749, "principal_investigator": { "id": 6247, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Planned COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24 months. The trial participants will be selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials will need to interact with trial participants during regular visits as well as conducting in-person assessments of all vaccine trial participants with symptoms that could be due to COVID-19 disease. This will result in close contact between study staff and high-risk participants or infected participants. As a result, study staff need to access a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, as well as the ability to sanitize hands frequently. This combination of PPE will be used during all risky interactions with study participants, such as during nasal swab collection and during evaluation of participants for possible study endpoints, including symptomatic COVID-19 disease. In addition, all staff will need to wear surgical face masks during and throughout their normal workday in the health care setting or on site for mobile study satellite sites. Without appropriate PPE, health care workers are vulnerable to infection with COVID-19, as well as passively transmitting to persons with whom they are in close physical contact. Access to adequate PPE is a critical component of the safe and effective conduct of COVID-19 vaccine trials, and will enable accurate determination of the study endpoints, especially symptomatic COVID- 19 disease.", "keywords": [ "COVID-19", "COVID-19 vaccine", "Clinical Research", "Clinical Treatment", "Clinical Trials", "Collection", "Communities", "Disease", "Enrollment", "Evaluation", "Face", "Goggles", "Hand", "Health Personnel", "Infection", "Participant", "Persons", "Resources", "Risk", "SARS-CoV-2 infection", "Site", "Symptoms", "Vaccines", "Visit", "base", "health care settings", "high risk", "nasal swab", "personal protective equipment", "screening", "surgical mask", "symptomatic COVID-19", "transmission process", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "9226", "attributes": { "award_id": "75N92020C00034-P00001-9999-1", "title": "RADX-TECH - ELLUME USA, LLC COVID-19 ANTIGEN TEST FOR THE DIRECT DETECTION OF THE SARS COV-2 VIRUS.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 21470000, "principal_investigator": { "id": 24967, "first_name": "SCOTT", "last_name": "FRY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A point-of-care, in vitro diagnostic test for the detection of an acute COVID 19 infection for use by healthcare professionals. The test will detect the nucleoprotein antigen of the SARS-CoV-2 virus from a healthcare provider-collected mid-turbinate nasal swab using a hand-held digital platform. The test system is connected to a cloud platform to provide real time access to patient test results by public health authorities for surveillance and monitoring. The test system includes: 1) a single-use test cartridge that connects to the hand-held digital platform 2) a sample collection and processing device 3) a squeezable vial containing a fixed volume of extraction fluid 4) ellume.lab, a hand-held digital platform designed to display test results and provide connectivity to Ellume's cloud. 5) a cloud database and interface for real time data collection, analytics and sharing The test is based on Ellume's established fluorescent immunoassay cartridge with digital detection technology, and leverages a proprietary fluorescence biosensor, with a light signature produced by quantum dot nanoparticles detected and digitized by a highly sensitive but fully disposable optoelectronics package. Ellume.lab, Ellume's digital platform, is a hand-held smart device that can read 2 test cartridges at a time. The device provides a digital user interface and includes step-by-step test instructions, digital interpretation of test results, and is connected to Ellume's cloud platform. The device also connects to the clinic's electronic medical record (EMR) system. The device requires no calibration or maintenance, and is battery operated with over 24 hours use before requiring charging.", "keywords": [ "Acute", "Biosensor", "COVID-19 detection", "Calibration", "Charge", "Clinic", "Computerized Medical Record", "Data Collection", "Databases", "Detection", "Devices", "Fluorescence", "Hand", "Health Personnel", "Health Professional", "Hour", "Immunoassay", "Instruction", "Light", "Liquid substance", "Maintenance", "Monitor", "Nasal turbinate bone structure", "Nucleoproteins", "Patients", "Public Health", "Quantum Dots", "RADx Tech", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Step Tests", "System", "Technology", "Test Result", "Testing", "Time", "Vial device", "Virus", "antigen test", "authority", "base", "cloud platform", "design", "detection test", "digital", "in-vitro diagnostics", "nanoparticle", "nasal swab", "point of care", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "9039", "attributes": { "award_id": "75N91019D00024-P00002-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 24161705, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Coronavirus", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } } ], "meta": { "pagination": { "page": 1419, "pages": 1424, "count": 14236 } } }